Translational nanoparticle engineering for cancer vaccines.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

27 citing papers in PubMed, 44 citations in OpenAlex.

1. Beyond the genetic code: orchestrating epigenetic and immune landscapes with multivalent mRNA-exosome vaccines.Precision clinical medicine · 2026
   Review
2. Virus-like particles in cancer immunotherapy: bridging human and veterinary medicine through one health.Journal of nanobiotechnology · 2026
   Review
3. Magnetic nanoparticles as promising materials for the future of medicine.Journal of materials science. Materials in medicine · 2026
   Review
4. Nanotechnology for immuno-oncology.Nature cancer · 2025
   Review
5. CEA-Functionalized Gold Nanoparticles as a Nanovaccine Platform: In Vitro Evaluation of Cytocompatibility, Cellular Uptake, and Antigen Processing.Vaccines · 2025
   Article
6. Functionalized PLGA-Based Nanoparticles with Anti-HSV-2 Human Monoclonal Antibody: A Proof of Concept for Early Diagnosis and Targeted Therapy.Pharmaceutics · 2024
   Article
7. Recent Review on Biological Barriers and Host-Material Interfaces in Precision Drug Delivery: Advancement in Biomaterial Engineering for Better Treatment Therapies.Pharmaceutics · 2024
   Review
8. Recent Findings on Therapeutic Cancer Vaccines: An Updated Review.Biomolecules · 2024
   Review
9. Revolutionizing head and neck squamous cell carcinoma treatment with nanomedicine in the era of immunotherapy.Frontiers in immunology · 2024
   Review
10. Aerosol pulmonary immune engineering.Advanced drug delivery reviews · 2023
    Review
11. Knowledge mapping of therapeutic cancer vaccine from 2013 to 2022: A bibliometric and visual analysis.Human vaccines & immunotherapeutics · 2023
    Review
12. Peptide-based vaccine for cancer therapies.Frontiers in immunology · 2023
    Review
13. Pharmacological impact of microRNAs in head and neck squamous cell carcinoma: Prevailing insights on molecular pathways, diagnosis, and nanomedicine treatment.Frontiers in pharmacology · 2023
    Review
14. Gold Nanorods for Drug and Gene Delivery: An Overview of Recent Advancements.Pharmaceutics · 2022
    Review
15. The role of T-cells in head and neck squamous cell carcinoma: From immunity to immunotherapy.Frontiers in oncology · 2022
    Review
16. Magnetic systems for cancer immunotherapy.Acta pharmaceutica Sinica. B · 2021
    Review
17. Bio-Nanocarriers for Lung Cancer Management: Befriending the Barriers.Nano-micro letters · 2021
    Review
18. Engineering precision nanoparticles for drug delivery.Nature reviews. Drug discovery · 2021
    Review
19. Nanoparticles as immunomodulators and translational agents in brain tumors.Journal of neuro-oncology · 2021
    Review
20. Chitosan Nanovaccines as Efficient Carrier Adjuvant System for IL-12 with Enhanced Protection Against HBV.International journal of nanomedicine · 2021
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors at 2 institutions in 1 country.

Funding

Abstract

Indexed as